Real-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic
Affiliation
The Christie Hospital, Manchester, United KingdomIssue Date
2024
Metadata
Show full item recordCitation
Fabio G, Niall G, Vivian T, Katerina C, Joanne R, Amine A, et al. Real-world analysis of the impact of pemetrexed in firstline maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic. Lung cancer (Amsterdam, Netherlands). 2024 APR;190:52-. PubMed PMID: WOS:001231921600001. English.Journal
Lung CancerDOI
10.1016/j.lungcan.2024.107662Additional Links
https://dx.doi.org/10.1016/j.lungcan.2024.107662Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.lungcan.2024.107662